Searching News Database: pseudobulbar affect
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 16 Mar 2012
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as Chief Commercial Officer
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
Additional items found! 17
Members Archive contains
17 additional stories matching:
pseudobulbar affect
(Password required)
pseudobulbar affect
(Password required)